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ABSTRACT
Introduction: The era of biologic therapies has
provided new options for the treatment of
chronic plaque psoriasis. However, safety
concerns have led to intensive screening and
monitoring of patients receiving anti-tumor
necrosis factor alpha (anti-TNF-alpha) agents.
Methods: The authors describe the cases of
three patients with moderate to severe
psoriasis treated with anti-TNF agents, with
challenging diagnostic and treatment aspects
regarding tuberculosis (TB) infection, a serious
adverse event associated with this type of
treatment. The cases are discussed in the
context of a comprehensive literature review
describing the risk of TB associated with the use
of TNF inhibitors. A critical review of the
clinical trials that have tested the safety of
these agents is also presented.
Results: One patient, who tested negatively for
latent TB infection (LTBI) during screening,
developed active TB under adalimumab
therapy. For two other patients the diagnosis
and management of LTBI in relation to anti-
TNF therapy represented a challenge. Although
clinical trials involving the use of anti-TNF
therapy for psoriasis haven’t demonstrated a
high TB incidence, active TB is continuously
reported in association with this treatment.
Conclusions: Findings from clinical practice
and the scientific literature indicate that anti-
TNF therapies are associated with an increased
risk of TB, and close monitoring of patients is
needed.
Keywords: Adalimumab; Biologic therapy;
Dermatology; Etanercept; Infliximab; Psoriasis;
Tuberculosis; Tumor necrosis factor
INTRODUCTION
Psoriasis is a chronic inflammatory systemic
disease predominantly affecting the skin and
joints. The prevalence ranges between 0.9%
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(United States) and 8.5% (Norway) [1]. Skin
lesions are the major manifestation of the
disease. They are described as scaling and
erythematous plaques that may be pruritic or
painful and cause significant quality of life
issues [2].
The new era of biologic therapies offers
outstanding options for the treatment of
chronic plaque psoriasis, and these agents
have proved to be remarkable in improving
patient quality of life compared with classical
antipsoriatic treatments. However, despite the
high efficacy, there have always been concerns
regarding the safety of these agents as all anti-
tumor necrosis factor alpha (anti-TNF-alpha)
agents have been associated with activation
of latent tuberculosis infection (LTBI) in a
relatively short period of time [3]. According
to World Health Organization (WHO), the
global incidence of tuberculosis (TB) is
estimated to 125 cases per 100,000 population
[4]. The progression or reactivation of TB
should be expected and such concerns have
led to intensive screening and monitoring of
patients receiving anti-TNF therapies [5].
Current screening includes medical history,
chest X-ray, and tests for evaluating the
immunologic response to the presence of
Mycobacterium tuberculosis, such as the
tuberculin skin test (TST) and interferon
gamma release assays (IGRAs) [6]. Current
guidelines recommend TST as the main
screening tool for LTBI in patients with
psoriasis before initiation of anti-TNF therapy,
but there is a lack of consensus on the
interpretation of TST in this group of patients
[7–9]. The European S3 guidelines recommend
the use of either TST or IGRAs or both for
LTBI detection [10]. However, as TST may
produce false-positive results, the newest
recommendations suggest the use of IGRAs
[11].
Despite the screening programs for LTBI
identification prior to anti-TNF therapy, the
risk of developing active TB is still present. We
report a patient with psoriasis who had a
negative TST during screening and later
developed active TB under adalimumab
therapy. We also report two patients with
challenging aspects regarding the diagnosis
and management of LTBI in relation to anti-
TNF therapy. Additional evidence from a review
of the literature is also discussed.
CASE STUDIES
Patient characteristics, TB status, and treatment
received for all three case studies are
summarized in Table 1.
Case 1
A 57-year-old man presented with a 18-year
history of severe chronic plaque psoriasis. The
patient was hypertensive. He was previously
treated with systemic methotrexate and topical
antipsoriatic therapies. He did not report any
known contact with a case of active TB.
Due to the poor response to classical
treatments for psoriasis, adalimumab was
recommended according to current guidelines
[2]. All screening tests were within normal
ranges, including a negative TST (3 mm
induration) and chest X-ray. Therefore,
adalimumab therapy was initiated without
antituberculous chemoprophylaxis. The
patient showed a good and stable response;
the Psoriasis Area and Severity Index (PASI)
decreased from 36 to 9 in 12 weeks, and all
lesions were cleared after 6 months of
treatment.
After 18 months of biologic therapy, the
patient complained of a mild but persistent
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cough and loss of appetite. A subsequent TST
was positive (17 mm). QuantiFeron-TB Gold
(QFT-G) test (Cellestis Inc., Valencia, CA, USA)
was also positive. Chest X-ray and computed
tomography (CT) both showed bilateral
pulmonary infiltrates. Routine laboratory
examinations, including complete blood count
and biochemical profile, were within normal
limits. The patient was referred to a
pulmonologist who confirmed active
pulmonary TB with positive microbiology.
The patient discontinued adalimumab and
tuberculostatic treatment was prescribed. After
a 6-month course of a multidrug anti-TB
regimen, the pulmonary lesions were
completely cleared but the psoriasis
progressively worsened. With the patient’s
consent and the pneumologist’s approval,
adalimumab was resumed with close follow-up.
After 6 months of follow-up, there was a
marked improvement in the patient’s psoriasis
and no report of any other side effects. Close
monitoring of the patient will continue in order
to rule out TB recurrence.
Case 2
A 53-year-old woman presented with a 9-year
history of psoriasis vulgaris and psoriatic
arthritis. She was previously treated with
systemic methotrexate, leflunomide,
sulfasalazine, and topical antipsoriatic
therapies. She did not report any contact with a
case of active TB.
The patient was screened before
administration of biologic therapy. The
patient’s TST value was 24 mm. Chest X-ray
was negative. Clinical examination and
routine laboratory tests were normal.
Chemoprophylaxis with isoniazid (300 mg/
day, 9 months) was prescribed, which was
initiated 1 month before anti-TNF therapy.
Subsequent treatment with infliximab was
associated with a good response and complete
clearing of skin lesions. Annual TST testing
remained high in two repeated determinations
(25, respectively 30 mm). No side effects were
noted in the first 2 years of treatment.
After 30 months of biologic therapy, the TST
was 35 mm, QFT-G was also positive, and a chest
x-ray showed two pulmonary nodular lesions.
CT showed two fibronodular infiltrates in the
inferior lobe of left lung and middle lobe of the
right lung. Routine laboratory tests were within
normal limits. The patient was asymptomatic,
but was referred to a pneumologist who,
based on clinical suspicion, recommended
interruption of anti-TNF therapy and initiation
of a tuberculostatic regimen. However, the
sputum specimens were negative for M.
tuberculosis by smear and culture, and active TB
was finally infirmed. The patient was diagnosed
with LTBI, resuming biologic therapy with
another biologic agent: etanercept. The patient
developed a persistent injection-site reaction
after four doses of etanercept, a side effect that
led to cessation of this anti-TNF treatment and
initiation of adalimumab as an alternative
treatment. The patient’s condition is currently
stable, with a continued response to
adalimumab and no side effects after 6 months
of follow-up. Close monitoring will continue in
order to rule out reactivation of LTBI.
Case 3
A 64-year-old woman presented with a 21-year
history of psoriasis. She suffered from psoriatic
arthritis, type 2 diabetes mellitus, asthma,
hypertension, atopy, and obesity. The patient
reported allergic reactions to various
medications, including penicillin, mometasone
furoate, and aspirin. She had previously
received systemic methotrexate and psoralen
62 Infect Dis Ther (2013) 2:59–73
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combined with ultraviolet A (PUVA) therapy
and did not report any known contact with a
case of active TB.
Prior to initiation of anti-TNF treatment with
infliximab, she had undergone a TST with an
induration of 15 mm and a positive QFT-G
assay. Chest X-ray showed a calcified left
apical fibronodule. Physical examination did
not reveal any pathological findings. Routine
laboratory tests were within normal range.
The patient was diagnosed with LTBI and
chemoprophylaxis with isoniazid 300 mg/day
was prescribed. After 2 months of isoniazid, she
developed erythema multiforme and treatment
was stopped. An attempt was made to
reintroduce the chemoprophylactic treatment
but the skin lesions reappeared.
Due to the severity of her condition (severe
psoriasis with a PASI score of 31 and psoriatic
arthritis), she continued infliximab therapy
with close pneumology follow-up. After the
fourth infusion, she developed an anaphylaxis-
like reaction to infliximab. The drug was
discontinued and the patient was switched to
adalimumab. The patient was treated
successfully with adalimumab for 2 years
without side effects. Monitoring will continue
in order to rule out active TB.
DISCUSSION
The advent of anti-TNF agents has
revolutionized the therapeutic approach to
psoriasis and other inflammatory disorders.
However, as these therapies have become
widely used in clinical practice, TB is
increasingly recorded. The authors presented
three cases of patients with challenging aspects
regarding the risk of TB related to anti-TNF
therapy. The first patient, excluding his
psoriasis, was an otherwise healthy individual
with no predisposing factors for TB. A TST
response of 3 mm during the screening was
considered negative. This suggests that even
healthy individuals with no predisposing
factors or evidence of LTBI should be
cautiously monitored. The second patient
started a multidrug anti-TB regimen, but the
diagnosis of active TB was finally infirmed. In
contrast, the third patient was diagnosed with
LTBI and was treated successfully with biologic
therapy for more than 2 years, despite a short
course of a chemoprophylactic regimen with
isoniazid.
TNF-alpha is a pro-inflammatory cytokine
that stimulates the acute phase reaction. It has a
broad spectrum of biologic effects: it stimulates
inflammatory cytokines (interleukin [IL]-1beta,
IL-6, IL-8, granulocyte–macrophage colony-
stimulating factor [GM-CSF]) and chemokines
(monocyte chemotactic protein-1 [MCP-1],
Macrophage inflammatory protein [MIP]-
1alpha, MIP-2, RANTES [regulated and normal
T cell expressed and secreted]) [12], activates
endothelial adhesion molecules (vascular cell
adhesion molecule 1 [VCAM-1], intercellular
Adhesion Molecule 1 [ICAM-1], E-selectin),
induces apoptosis, and inhibits tumorigenesis
and viral replication. TNF-alpha is important in
the protection against M. tuberculosis through
its role in granuloma formation. It recruits
macrophages and lymphocytes, and is required
for the maintenance of the granulomatous
structure [13, 14].
The cytokines released by T cells play a
critical role in TB pathogenesis through
macrophage activation and granuloma
formation. T-helper 1 (Th1) lymphocytes
release interferon-gamma (IFN-c) and TNF-
alpha. These cytokines are involved in the
transformation of macrophages into
specialized histiocytic cells with bactericidal
and bacteriostatic functions. Activated
Infect Dis Ther (2013) 2:59–73 63
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macrophages, under T-lymphocyte influence,
organize and form the tuberculoid granulomas.
In contrast, TNF-blockade is associated with
granuloma lysis [9, 15].
Many randomized, controlled studies have
evaluated the safety of etanercept, infliximab,
and adalimumab [16, 17], the majority of which
have been conducted in patients with
rheumatologic conditions or Crohn’s disease.
However, according to the Food and Drug
Administration (FDA) Adverse Event Reporting
System (AERS), only a single case of TB occurred
during initial clinical trials of infliximab [18]
and none of the patients treated with
etanercept and adalimumab developed TB
during the initial studies [9]. Despite these
results, TB has been continuously reported in
association with biologic therapy [19–22].
Data from the British Society for
Rheumatology Biologics Register (BSRBR),
analyzing 10,712 patients with rheumatoid
arthritis treated with anti-TNF agents, reported
39 cases of active TB. The risk for TB was as
follows: 144 events/100,000 patient-years
for adalimumab; 136/100,000 patient-years
for infliximab; and 39/100,000 patient-years
for etanercept, confirming that infliximab and
adalimumab are associated with a three- to
fourfold higher rate of TB compared with
etanercept. The median time to TB diagnosis
was 13.4 months for patients exposed to
etanercept, 5.5 months for infliximab, and
18.5 months for patients exposed to
adalimumab [20]. Other publications have
indicated a lower risk of TB in patients treated
with etanercept compared with infliximab or
adalimumab [17, 22–27].
The safety data from patients with
rheumatoid arthritis can only partially be
generalized to patients with psoriasis vulgaris,
as psoriasis is typically treated with
monotherapy whereas rheumatoid arthritis is
commonly based on treatment regimens
consisting of systemic immunosuppressants
and biologics, which can increase the risk of
infection [28].
The present authors searched the MEDLINE
database for randomized, placebo-controlled
studies of the three currently used anti-TNF
agents (infliximab, etanercept, and
adalimumab) published between 2003 and
2012. Study participants were adult patients
with moderate-to-severe psoriasis treated with
anti-TNF agents for at least 12 weeks. Based on
these criteria, 13 clinical trials [29–41] were
identified that collectively included 3,657 adult
patients with moderate-to-severe psoriasis who
were treated with adalimumab, etanercept,
or infliximab (Table 2). The total number of
patients receiving the placebo was 1,709. The
treatment duration ranged from 12 to 52 weeks.
All trials compared anti-TNF agents with the
placebo: three trials with adalimumab, six trials
with etanercept, and four trials with infliximab.
Three studies [29, 40, 41] reported active TB as
an adverse event occurring during anti-TNF
therapy: one patient was treated with
adalimumab and five patients received
infliximab. Active TB was not reported in the
placebo group.
Although clinical trials have demonstrated
significant efficacy and a low number of TB
cases in patients with psoriasis, questions
remain about the long-term use of these
agents. There are several limitations that make
it difficult to assess the potential for anti-TNF
therapy to promote TB infection. For example,
the median time to TB diagnosis has been
reported to range from 5.5 to 18.5 months
[20], and these randomized, controlled studies
extend to a limited period of time
(3–13 months). From another point of view,
the study of Yang et al. [41] highlights that
TB is a major problem in endemic areas.
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Furthermore, clinical practice continues to
provide details concerning the increasing
numbers of patients with active TB, despite
the screening methods for detecting LTBI
[42–47].
TB often presents as extrapulmonary or
disseminated disease in such patients and has
been reported with the use of all of the anti-TNF
agents [15, 18, 21, 48–51]. This form of
presentation is explained by the underlying
mechanism: the immunosuppression induced
by anti-TNF therapy leads to reactivation
of secondary foci and dissemination of
M. tuberculosis [52]. The monoclonal antibodies
form stable complexes with all forms of TNF-
alpha, including TNF on the surface of
macrophages and T cells, which induces T cell
and macrophage apoptosis [53, 54]. In addition,
biologic therapy inhibits the Th1 cell response, as
well as the production of IFN, a cytokine with
major roles in the immune defense against M.
tuberculosis [55, 56]. Thus, these actions disturb
granuloma integrity and increase the risk of
secondary foci reactivation [52].
Active TB associated with biologic treatment
is believed to be the result of LTBI reactivation
in most cases. LTBI is defined as a complex
clinical condition in which an infection with
M. tuberculosis persists in a subclinical status
with minimal replication. The bacilli are unable
to cause clinical manifestations and cannot be
identified in culture [57]. Identification of latent
infection and chemoprophylaxis with isoniazid
seems to decrease the risk of developing active
disease [58]. Thus, an important prophylactic
measure is the treatment of LTBI [59]. This
approach reduces the reactivation risk by over
80% [60, 61]. However, de novo TB has also
been reported [62, 63]. A short time to the onset
of TB after the start of biologic treatment
suggests LTBI reactivation as the new
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anti-TNF treatment. De novo TB is not
influenced by anti-LTBI treatments. In these
cases, new approaches are required, such as
primary prevention [64].
Although current guidelines recommend
screening prior to anti-TNF therapy, there are
no standard indications and there is a lack of
consensus on interpreting TST in patients with
psoriasis. The consensus guidelines from the
National Psoriasis Foundation, USA, state that
an induration [5 mm is classified as positive in
patients with immunosuppression, including
patients who are receiving TNF antagonists [7].
The main disadvantage is that they do not
provide specific guidelines on interpreting TST
for patients about to start anti-TNF therapy [8].
Some authors consider that skin indurations of
5 mm or greater should be interpreted as a
positive result for LTBI in any patient
considered for TNF blockade [65]. This cut-off
value is accepted by most guidelines, including
the national guidelines, but it may overestimate
LTBI in psoriatic patients, leading to unnecessary
treatments. The present authors previously
reported that patients with moderate-to-severe
psoriasis had positive TST reactions more
frequently (70.5%) than nondermatologic
subjects (51%) [66]. Although the TST still
represents a useful method, it is difficult to
perform and read in psoriatic patients with
extensive lesions, because these patients rarely
present clinically unaffected skin for testing.
Moreover, important immunologic
mechanisms take place in even apparently
healthy skin of psoriatic patients; the
proinflammatory state can lead to an
overreaction to antigenic triggers [67]. Another
factor that may lead to false-positive results is the
Koebner phenomenon (development of psoriatic
lesions at the site of trauma), reported after
intradermal injection of purified protein
derivative (PPD) in psoriatic patients [68]. In
contrast, psoriatic patients with negative TST
results and positive QFT-G results have been
reported [69–71]. The reversion of a positive TST
result to a negative result may also occur [72].
Thus, to minimize the risk of false-negative
results, some authors propose a booster dose
7–10 days after an initially negative TST [73].
Tubach et al. [3] reported 69 cases of TB in
patients treated with anti-TNF agents, two-thirds
of which occurred in patients with negative TST
results at screening. However, the authors
suggested that both reactivation of LTBI during
the first year of treatment and new infections
occurring during follow-up were responsible for
the high incidence of TB reported in their study.
IGRAs are alternative tools for TB diagnosis.
The principle of these methods is based on the
detection of IFN-c produced by the effectors
memory T cells upon in vitro stimulation with
the TB-specific antigens, early secretory antigen
(ESAT) 6 and culture filtrate protein (CFP) 10.
IFN can be measured using either ELISpot-based
assay, represented by T-SPOT.TB
(Immunotech, Abingdon, UK), or an enzyme-
linked immunosorbent assay (ELISA),
represented by QFT-G and QFT-in-tube (QFT-
IT; Cellestis, Victoria, Australia) [74]. Although
QFT-G demonstrates high specificity for LTBI
(96–99%), its sensitivity is still questionable
(70–78%) [75]. In one study, LTBI treatment
was avoided in 20% of patients with positive
TST results but negative IGRA results [76].
The use of both methods in parallel can
enhance both sensitivity and specificity.
Furthermore, routine periodic retesting during
therapy could allow for the detection of possible
conversions. However, serial TST testing is not
strictly recommended due to the boosting effect
[60]. There is also evidence that the TST can boost
subsequentIGRAresults.Theeffect isevidentafter
the first 3 days post-TST testing and potentially
wanes after a few months [77]. Furthermore, the
68 Infect Dis Ther (2013) 2:59–73
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use of IGRAs during immunosuppressive
treatment (including biologic therapy) is
controversial, because the immunosuppression
might decrease the production of IFN and
interfere with the results [74].
Another inconvenience for both TST and
IGRAs is the lack of discrimination between
latent and active TB [60]. Positive TST/IGRAs
tests at baseline often remain positive despite a
successful anti-TB treatment. In these cases
careful monitoring for clinical signs and
symptoms of active TB is recommended [78].
According to the Tuberculosis Network
European Trials Group (TBNET) consensus, the
chemoprophylactic regimens recommended for
LTBI include 6 or 9 months with isoniazid,
3 months of rifampicin plus isoniazid, or
4 months of rifampicin [79]. Another regimen
used in the USA includes rifampicin and
pyrazinamide for 2 months, although this
regimen has been associated with a high
number of side effects [80].
The diagnostic tools for active TB infection
include clinical assessment, cultures for M.
tuberculosis, staining for acid-fast bacilli, chest
X-rays, and nucleic acid amplification assays [9].
Although culture is considered the reference
standard, in clinical practice the diagnosis and
treatment of TB are usually based on the presence
of abnormal radiologic findings or clinical
suspicion [20].
The recommendations for resuming biologic
therapy in active TB patients are controversial.
According to the American College of
Rheumatology (ACR), anti-TNF therapy can be
initiated or resumed after 1 month of
chemoprophylaxis for LTBI and after
completion of therapy for active disease [78].
The British Society for Rheumatology (BSR)
accepts the continuation of biologic therapy
during TB treatment if clinically indicated [81].
Hernandez et al. [82] reported 27 patients with
active TB that resumed anti-TNF therapy before
completing tuberculostatic treatment, without
relapse during a 4-year follow-up.
In conclusion, anti-TNF agents are an
established option for the treatment of
psoriasis, but the safety profile should be
carefully monitored. Even otherwise healthy
patients with no predisposing factors for TB
should be cautiously managed during biologic
therapy. It is mandatory for the dermatologists
who prescribe anti-TNF agents to carefully
evaluate the patients to exclude concomitant
TB and non-TB infections. Continuous vigilance,
long-term follow-up, and systematic reporting of
any suspected association between active TB and
biologic therapy will improve the prevention and
management of this complication.
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